US Bancorp
RPRX icon

US Bancorp’s Royalty Pharma RPRX Stock Holding History

US Bancorp’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$653K Buy
11,641
+777
+7% +$40.4K ﹤0.01% 1425
2026
Q1 		$521K Sell
10,864
-2,690
-20% -$118K ﹤0.01% 1487
2025
Q4 		$524K Sell
13,554
-868
-6% -$33.1K ﹤0.01% 1505
2025
Q3 		$509K Buy
14,422
+4
+0% +$145 ﹤0.01% 1490
2025
Q2 		$519K Buy
14,418
+935
+7% +$31K ﹤0.01% 1481
2025
Q1 		$420K Buy
13,483
+3,918
+41% +$124K ﹤0.01% 1586
2024
Q4 		$244K Buy
9,565
+5,759
+151% +$153K ﹤0.01% 1920
2024
Q3 		$108K Sell
3,806
-2,050
-35% -$56.8K ﹤0.01% 2363
2024
Q2 		$154K Sell
5,856
-3,527
-38% -$97.8K ﹤0.01% 2127
2024
Q1 		$285K Buy
9,383
+864
+10% +$25.5K ﹤0.01% 1825
2023
Q4 		$239K Buy
8,519
+4,759
+127% +$131K ﹤0.01% 1919
2023
Q3 		$102K Buy
3,760
+1,469
+64% +$43.6K ﹤0.01% 2137
2023
Q2 		$70.4K Sell
2,291
-3,248
-59% -$110K ﹤0.01% 2347
2023
Q1 		$200K Buy
5,539
+1,184
+27% +$43.9K ﹤0.01% 1864
2022
Q4 		$172K Sell
4,355
-626
-13% -$26.1K ﹤0.01% 1944
2022
Q3 		$201K Sell
4,981
-6,889
-58% -$294K ﹤0.01% 1850
2022
Q2 		$499K Buy
11,870
+765
+7% +$31.4K ﹤0.01% 1440
2022
Q1 		$433K Buy
11,105
+3,608
+48% +$142K ﹤0.01% 1593
2021
Q4 		$299K Buy
+7,497
New +$291K ﹤0.01% 1788
2021
Q3 		– Sell
-928
Closed -$38K – 4169
2021
Q2 		$38K Buy
928
+23
+3% +$978 ﹤0.01% 2804
2021
Q1 		$39K Hold
905
– – ﹤0.01% 2703
2020
Q4 		$45K Hold
905
– – ﹤0.01% 2557
2020
Q3 		$38K Hold
905
– – ﹤0.01% 2528
2020
Q2 		$44K Buy
+905
New +$44.8K ﹤0.01% 2479

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

US Bancorp's RPRX Position: Q2 2026 in Review

US Bancorp increased its Royalty Pharma (RPRX) stake by 7.2% in Q2 2026, buying an estimated $40.4K and bringing the position to 11,641 shares worth $653K. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

US Bancorp first reported a position in RPRX in Q2 2020 and has held it in 24 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • US Bancorp held 11,641 shares of Royalty Pharma worth $653K as of Q2 2026.
  • US Bancorp bought 777 Royalty Pharma shares in Q2 2026, an estimated $40.4K.
  • Royalty Pharma made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1425 holding.
  • US Bancorp first reported a position in Royalty Pharma in Q2 2020 and has held it in 24 quarters since.
  • 643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.